翔宇医疗(688626) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 was CNY 743.53 million, a decrease of 0.17% compared to the previous year[5] - Net profit attributable to the parent company was CNY 103.49 million, down 54.44% year-on-year[5] - Net profit attributable to the parent company after deducting non-recurring gains and losses was CNY 90.47 million, a decrease of 55.66% compared to the previous year[5] - Basic earnings per share decreased to CNY 0.66, down 54.17% from CNY 1.44 in the previous year[5] - The weighted average return on net assets decreased to 5.04%, down 6.25 percentage points from the previous year[3] Assets and Equity - Total assets increased to CNY 2,931.79 million, reflecting a growth of 13.10% year-on-year[5] - Equity attributable to the parent company decreased to CNY 2,039.23 million, a decline of 2.47% compared to the previous year[5] Operational Challenges - The company faced increased R&D personnel costs and depreciation expenses, impacting net profit[6] - The company maintained stable revenue while investing in high-end rehabilitation technology talent and R&D personnel[5] Strategic Focus - The company emphasizes technological innovation and management improvement to enhance operational capabilities[5]